×
Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Monkeypox Vaccine Treatment Market

ID: MRFR/Pharma/42095-HCR
200 Pages
Garvit Vyas
October 2025

Monkeypox Vaccine and Treatment Market Research Report By Product Type (Vaccines, Therapeutics, Diagnostics), By Administration Route (Intravenous, Subcutaneous, Intramuscular), By End User (Hospitals, Clinics, Pharmaceutical Companies, Research Institutions), By Distribution Channel (Pharmacies, Online Pharmacies, Hospitals) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Monkeypox Vaccine Treatment Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Monkeypox Vaccine Treatment Market Summary

As per MRFR analysis, the Monkeypox Vaccine Treatment Market Size was estimated at 374.29 USD Million in 2024. The Monkeypox Vaccine Treatment industry is projected to grow from 424.52 in 2025 to 1495.51 by 2035, exhibiting a compound annual growth rate (CAGR) of 13.42 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Monkeypox Vaccine Treatment Market is experiencing robust growth driven by increased public health initiatives and technological advancements.

  • North America remains the largest market for monkeypox vaccines, reflecting a strong focus on public health measures.
  • The Asia-Pacific region is emerging as the fastest-growing market, driven by rising awareness and healthcare investments.
  • Prevention is the largest segment, while post-exposure prophylaxis is witnessing the fastest growth due to heightened vigilance against outbreaks.
  • Rising incidence of monkeypox cases and government initiatives are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size 374.29 (USD Million)
2035 Market Size 1495.51 (USD Million)
CAGR (2025 - 2035) 13.42%

Major Players

Bavarian Nordic (DK), Janssen Pharmaceuticals (US), Siga Technologies (US), Merck & Co. (US), GSK (GB), Pfizer (US), Moderna (US), Sanofi (FR)

Monkeypox Vaccine Treatment Market Trends

The Monkeypox Vaccine Treatment Market is currently experiencing a notable evolution, driven by heightened awareness and concern regarding monkeypox outbreaks. This market appears to be influenced by various factors, including the increasing incidence of monkeypox cases globally and the subsequent demand for effective vaccination strategies. As governments and health organizations prioritize public health measures, the focus on developing and distributing vaccines has intensified. This trend suggests a growing recognition of the importance of vaccination in controlling infectious diseases, which may lead to increased investment in research and development within this sector. Moreover, the landscape of the Monkeypox Vaccine Treatment Market is characterized by collaboration among pharmaceutical companies, governmental bodies, and international health organizations. Such partnerships seem to facilitate the rapid advancement of vaccine technologies and distribution networks. The ongoing efforts to enhance vaccine accessibility and affordability indicate a commitment to ensuring that populations at risk receive timely protection. As the market continues to evolve, it is likely that innovations in vaccine formulation and delivery methods will emerge, potentially reshaping the approach to monkeypox prevention and treatment in the coming years.

Increased Research and Development

The Monkeypox Vaccine Treatment Market is witnessing a surge in research and development activities. This trend indicates a commitment to understanding the virus better and creating more effective vaccines. Pharmaceutical companies are likely investing in innovative technologies to enhance vaccine efficacy and safety.

Global Collaboration Efforts

There appears to be a growing trend of collaboration among various stakeholders in the Monkeypox Vaccine Treatment Market. Governments, health organizations, and private companies are increasingly working together to address the challenges posed by monkeypox. Such partnerships may lead to improved vaccine distribution and accessibility.

Public Awareness and Education

The importance of public awareness regarding monkeypox vaccination is becoming more pronounced. Educational campaigns seem to be gaining traction, aiming to inform communities about the benefits of vaccination. This trend could potentially lead to higher vaccination rates and better public health outcomes.

Monkeypox Vaccine Treatment Market Drivers

Rising Incidence of Monkeypox Cases

The increasing incidence of monkeypox cases globally is a primary driver for the Global Monkeypox Vaccine and Treatment Market Industry. Reports indicate that the number of confirmed monkeypox cases has surged, prompting health authorities to prioritize vaccination and treatment strategies. This rise in cases has led to heightened awareness and urgency among governments and healthcare organizations to develop and distribute effective vaccines. As a result, the market is projected to grow from 0.38 USD Billion in 2024 to an estimated 1.5 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 13.29% from 2025 to 2035.

Market Segment Insights

By Application: Prevention (Largest) vs. Post-Exposure Prophylaxis (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the application segment is primarily dominated by prevention efforts, which constitute the largest share. This segment emphasizes the proactive administration of vaccines to high-risk populations, reflecting a societal focus on curbing outbreaks before they start. In contrast, post-exposure prophylaxis, although smaller in share, is gaining traction, especially in contexts where exposure to the virus has occurred. This shift is indicative of evolving public health strategies that prioritize immediate response measures alongside prevention efforts. The growth trends for these application categories show a pronounced driver towards prevention, influenced by heightened awareness and education surrounding monkeypox in the wake of recent outbreaks. The speed of expansion in post-exposure prophylaxis is fueled by the quick acknowledgment of exposure risks, ensuring that rapid responses are prioritized in treatment protocols. Overall, the interplay between preventative measures and reactive treatments is shaping how stakeholders strategize in the market, with each facet contributing distinctly to overall public health objectives.

Prevention (Dominant) vs. Post-Exposure Prophylaxis (Emerging)

Prevention plays a pivotal role in the Monkeypox Vaccine Treatment Market, serving as the dominant approach to disease control. Vaccines administered proactively safeguard high-risk populations and are backed by extensive public health initiatives. This preventive strategy is crucial in mitigating potential outbreaks, with a focus on ensuring that communities remain protected through widespread inoculation efforts. On the other hand, post-exposure prophylaxis is characterized as an emerging segment, quickly adapting to scenarios where individuals have been exposed to the virus. This proactive response enhances the overall effectiveness of vaccination strategies, emphasizing timely interventions to prevent disease manifestation. The sharp rise in demand for post-exposure measures highlights a crucial shift towards a more comprehensive approach to managing monkeypox outbreaks, balancing both preventive and reactive health strategies.

By Distribution Channel: Direct Sales (Largest) vs. Pharmacies (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the distribution channels are diverse, with Direct Sales capturing the largest share. This channel allows manufacturers to connect directly with healthcare providers and consumers, ensuring wider accessibility and streamlining the distribution process. Pharmacies, on the other hand, are emerging rapidly as a significant player. They not only provide convenience to consumers but also play a crucial role in vaccine administration and education about monkeypox treatment options. Growth trends indicate a shift towards online sales and pharmacies. Increased awareness and the need for accessible treatment options drive this change. Online sales have particularly surged due to the pandemic, as many consumers prefer the ease and safety of purchasing medications from home. The collaboration between healthcare institutions and pharmacies is expected to enhance distribution efficiency, further boosting market growth in this segment.

Direct Sales (Dominant) vs. Online Sales (Emerging)

Direct Sales remain the dominant distribution channel in the Monkeypox Vaccine Treatment Market, primarily due to the direct interaction with healthcare providers and quick response to market demands. This channel allows for better control over the supply chain, ensuring that vaccines reach healthcare institutions effectively. In contrast, Online Sales are emerging as a vital alternative, catering to a tech-savvy consumer base that appreciates the convenience of purchasing vaccines from the comfort of their homes. While Direct Sales rely on established relationships with healthcare entities, Online Sales leverage digital platforms to reach a broader audience. This evolution necessitates a shift in marketing strategies to optimize both channels, ensuring that the needs of various consumers and healthcare providers are met, ultimately leading to improved vaccination rates.

By End User: Healthcare Providers (Largest) vs. Government Agencies (Fastest-Growing)

The Monkeypox Vaccine Treatment Market is predominantly driven by Healthcare Providers who hold the largest share in the end-user segment. These providers include hospitals, clinics, and medical facilities that are on the front lines of administering vaccines. Their extensive networks facilitate the distribution and accessibility of vaccines, ensuring that the largest patient populations receive the necessary treatments in a timely manner. Government Agencies are also significant players, particularly as they implement public health initiatives responsive to infectious disease outbreaks, representing the fastest-growing segment due to increased funding and emphasis on community health security. As the Monkeypox virus continues to pose public health challenges, the demand from Government Agencies is expected to rise sharply. This surge is primarily influenced by heightened awareness of epidemic preparedness and the need for swift vaccination campaigns. In contrast, Healthcare Providers will maintain a steady demand driven by the ongoing requirement for vaccinations in healthcare settings. Innovations in vaccine delivery and the establishment of strategic partnerships between these providers and government bodies are likely to enhance growth across this segment, supporting rapid response capabilities and expanding vaccination outreach.

Healthcare Providers (Dominant) vs. Government Agencies (Emerging)

Healthcare Providers play a dominant role in the Monkeypox Vaccine Treatment Market, as they are responsible for direct vaccine administration and patient care. These entities include hospitals, clinics, and healthcare systems that provide a vital link between vaccine production and public vaccination efforts. Their infrastructure enables comprehensive vaccine distribution, ensuring that vulnerable populations receive timely vaccinations. In contrast, Government Agencies serve as emerging stakeholders, rapidly increasing their influence in vaccine distribution and public health policy. With escalating government initiatives aimed at managing health emergencies, these agencies are crucial for strategizing and implementing vaccination campaigns, thus complementing Healthcare Providers' efforts. The responsiveness of Government Agencies to emerging health threats positions them as important players in the evolving healthcare landscape.

By Formulation Type: Live Attenuated (Largest) vs. Inactivated (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the distribution of market share among formulation types reveals notable insights. The Live Attenuated Vaccine holds the largest share, recognized for its robust immune response and long-lasting efficacy. In contrast, Inactivated Vaccines are observed to be the fastest-growing segment due to increasing demand for safer alternatives that minimize potential side effects, attracting specific demographics such as those with compromised immune systems. Recent trends indicate a significant shift toward a preference for Inactivated Vaccines, supported by robust clinical data showcasing improved safety profiles. Additionally, advancements in biotechnology are enhancing the production of these vaccines, enabling quicker response times to outbreaks. This growing demand reflects global public health initiatives emphasizing preparedness and proactive vaccination strategies against monkeypox.

Live Attenuated (Dominant) vs. Inactivated (Emerging)

Live Attenuated Vaccines are recognized as the dominant formulation in the Monkeypox Vaccine Treatment Market, known for their ability to trigger strong immune responses and achieve long-lasting immunity through a single dose. These vaccines require careful handling and monitoring to mitigate risks associated with live pathogens. On the other hand, Inactivated Vaccines are emerging as a strong alternative, particularly appealing to vulnerable populations due to their enhanced safety profiles. As these vaccines undergo modernization and refinement, their market position is improving, supported by growing acceptance among healthcare providers and patients. The increasingly sophisticated manufacturing processes are set to boost production scalability and accessibility, which will play a crucial role in future vaccination campaigns.

By Storage Condition: Refrigerated (Largest) vs. Frozen (Fastest-Growing)

In the Monkeypox Vaccine Treatment Market, the storage conditions play a critical role in ensuring vaccine efficacy and stability. The largest segment is refrigerated storage, where a significant share of vaccines is maintained at controlled temperatures, crucial for preserving their effectiveness. Following closely is the frozen segment, which is rapidly gaining traction due to advancements in cryopreservation technologies. Essentially, while refrigerated storage remains a staple, frozen storage is carving out a notable niche.

Storage Condition: Refrigerated (Dominant) vs. Frozen (Emerging)

Refrigerated storage conditions dominate the Monkeypox Vaccine Treatment Market, providing a reliable option for maintaining vaccine integrity in a temperature-controlled environment. This method is widely accepted and utilized by healthcare providers, ensuring vaccines remain effective until administration. Conversely, the frozen segment is emerging as a vital alternative, appealing particularly to manufacturers looking to extend the shelf life of their products. With evolving technological innovations in storage methods, frozen storage is expected to experience significant growth driven by increasing demand for vaccines that can be transported and stored without immediate refrigeration.

Get more detailed insights about Monkeypox Vaccine Treatment Market
Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America is poised to maintain its leadership in the Monkeypox vaccine treatment market, holding a significant share of 187.15M in 2025. The region's growth is driven by robust healthcare infrastructure, increasing awareness of infectious diseases, and proactive regulatory measures. The U.S. government has been instrumental in funding vaccine development and distribution, ensuring rapid response capabilities against outbreaks. The competitive landscape is characterized by major players such as Janssen Pharmaceuticals, Merck & Co., and Moderna, which are actively engaged in research and development. The presence of these key players, along with strategic partnerships and collaborations, enhances market dynamics. The U.S. is expected to remain the leading country, supported by favorable policies and a strong focus on public health initiatives.

Europe : Emerging Market with Growth Potential

Europe is witnessing a growing interest in the Monkeypox vaccine treatment market, with a market size of 100.0M in 2025. The region's growth is fueled by increasing cases of monkeypox and heightened public health awareness. Regulatory bodies are actively working to streamline vaccine approvals, which is expected to enhance market accessibility and drive demand. The European Medicines Agency (EMA) is focusing on expediting the review process for vaccines targeting emerging infectious diseases. Leading countries in this region include Germany, France, and the UK, where significant investments in healthcare infrastructure are being made. Key players like GSK and Sanofi are expanding their portfolios to include monkeypox vaccines, fostering a competitive environment. The collaboration between public health organizations and pharmaceutical companies is crucial for addressing the rising health concerns associated with monkeypox.

Asia-Pacific : Growing Awareness and Demand

The Asia-Pacific region is emerging as a significant player in the Monkeypox vaccine treatment market, with a market size of 60.0M in 2025. The growth is driven by increasing awareness of monkeypox and the need for effective vaccination strategies. Governments are prioritizing public health initiatives, which include the development and distribution of vaccines. Regulatory frameworks are evolving to support faster approvals for vaccines targeting infectious diseases. Countries like Japan, Australia, and India are at the forefront of this market, with local manufacturers and international collaborations enhancing vaccine availability. Key players such as Siga Technologies and Pfizer are exploring opportunities in this region, contributing to a competitive landscape. The focus on research and development, along with government support, is expected to drive market growth in the coming years.

Middle East and Africa : Emerging Market with Challenges

The Middle East and Africa region is gradually developing its Monkeypox vaccine treatment market, with a market size of 27.14M in 2025. The growth is hindered by infrastructural challenges and limited access to healthcare. However, increasing awareness of infectious diseases is prompting governments to invest in vaccine development and distribution. Regulatory bodies are beginning to prioritize the approval of vaccines for emerging diseases, which is crucial for public health. Leading countries in this region include South Africa and Nigeria, where efforts are being made to enhance healthcare systems. The presence of key players like Merck & Co. is vital for market growth, as they collaborate with local governments to improve vaccine access. The competitive landscape is evolving, with a focus on partnerships to address the unique challenges faced in this region.

Monkeypox Vaccine Treatment Market Regional Image

Key Players and Competitive Insights

The Monkeypox Vaccine Treatment Market is currently characterized by a dynamic competitive landscape, driven by increasing global awareness of infectious diseases and the need for effective vaccination strategies. Key players such as Bavarian Nordic (DK), Janssen Pharmaceuticals (US), and Siga Technologies (US) are actively shaping the market through innovative approaches and strategic partnerships. Bavarian Nordic (DK) has positioned itself as a leader in the development of vaccines, focusing on its proprietary technology to enhance efficacy and safety. Meanwhile, Janssen Pharmaceuticals (US) emphasizes its commitment to research and development, aiming to expand its portfolio in infectious disease prevention. Siga Technologies (US) is leveraging its expertise in antiviral therapeutics to complement its vaccine offerings, indicating a trend towards integrated treatment solutions.In terms of business tactics, companies are increasingly localizing manufacturing to enhance supply chain resilience and reduce lead times. This approach appears to be particularly relevant in the context of the Monkeypox Vaccine Treatment Market, which is moderately fragmented, with several players vying for market share. The collective influence of these key players is shaping a competitive structure that encourages innovation while also fostering collaboration among industry stakeholders.

In November Bavarian Nordic (DK) announced a strategic partnership with a leading biotechnology firm to co-develop a next-generation monkeypox vaccine. This collaboration is expected to enhance research capabilities and accelerate the development timeline, reflecting a broader trend of companies seeking synergies to bolster their R&D efforts. The strategic importance of this partnership lies in its potential to position Bavarian Nordic at the forefront of vaccine innovation, thereby enhancing its competitive edge.

In October Janssen Pharmaceuticals (US) launched a new initiative aimed at increasing vaccine accessibility in underserved regions. This initiative includes partnerships with local health organizations to facilitate distribution and education about monkeypox vaccination. The strategic significance of this move is twofold: it not only expands Janssen's market reach but also aligns with global health priorities, potentially enhancing its reputation as a socially responsible entity in the pharmaceutical sector.

In September Siga Technologies (US) secured a government contract worth $50M to supply its antiviral treatments alongside its vaccine offerings. This contract underscores the growing recognition of the importance of comprehensive treatment strategies in managing infectious diseases. The strategic implications of this development suggest that Siga is well-positioned to capitalize on the increasing demand for integrated healthcare solutions, thereby reinforcing its market presence.

As of December current competitive trends in the Monkeypox Vaccine Treatment Market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market dynamics. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition towards innovation, technological advancements, and supply chain reliability. This transition may ultimately redefine the landscape, emphasizing the importance of agility and responsiveness in meeting the needs of a rapidly changing global health environment.

Key Companies in the Monkeypox Vaccine Treatment Market include

Industry Developments

Recent news in the Monkeypox Vaccine and Treatment Market has shown significant developments, particularly as cases of monkeypox have surged in various regions. Notably, companies such as Siga Technologies and Bavarian Nordic are actively pursuing advancements in their vaccine formulations and treatments to meet growing demand.

Pfizer, Moderna, and other pharmaceutical giants like Merck Co. and Sanofi are exploring collaborative efforts to expedite vaccine production and improve distribution frameworks. Current affairs indicate that public health initiatives are ramping up vaccination campaigns, with governmental agencies emphasizing the importance of effective treatments amidst rising infection rates.

Moreover, market valuation for these companies has seen notable growth, driven by increasing investments and the critical need for enhanced public health responses. In terms of mergers and acquisitions, there have been talks regarding alliances among firms like Novavax and Inovio Pharmaceuticals to bolster research and development capabilities.

The competition in the market is intensifying with AstraZeneca and GSK also positioning themselves strategically to capitalize on this emerging health concern. Overall, the market is evolving rapidly, reflecting the urgency of addressing monkeypox through innovative vaccine and treatment solutions.

Future Outlook

Monkeypox Vaccine Treatment Market Future Outlook

The Monkeypox Vaccine Treatment Market is projected to grow at a 13.42% CAGR from 2025 to 2035, driven by rising awareness, increased vaccination initiatives, and global health policies.

New opportunities lie in:

  • Development of mobile vaccination units for remote areas.
  • Partnerships with healthcare providers for integrated vaccination programs.
  • Investment in research for next-generation vaccines targeting emerging strains.

By 2035, the market is expected to be robust, driven by innovative strategies and heightened global health initiatives.

Market Segmentation

Monkeypox Vaccine Treatment Market End User Outlook

  • Healthcare Providers
  • Government Agencies
  • Research Institutions
  • Pharmaceutical Companies

Monkeypox Vaccine Treatment Market Application Outlook

  • Prevention
  • Post-Exposure Prophylaxis
  • Treatment

Monkeypox Vaccine Treatment Market Formulation Type Outlook

  • Live Attenuated Vaccine
  • Inactivated Vaccine
  • Subunit Vaccine

Monkeypox Vaccine Treatment Market Storage Condition Outlook

  • Refrigerated
  • Frozen
  • Room Temperature

Monkeypox Vaccine Treatment Market Distribution Channel Outlook

  • Direct Sales
  • Pharmacies
  • Online Sales
  • Healthcare Institutions

Report Scope

MARKET SIZE 2024374.29(USD Million)
MARKET SIZE 2025424.52(USD Million)
MARKET SIZE 20351495.51(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)13.42% (2025 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Million
Key Companies ProfiledBavarian Nordic (DK), Janssen Pharmaceuticals (US), Siga Technologies (US), Merck & Co. (US), GSK (GB), Pfizer (US), Moderna (US), Sanofi (FR)
Segments CoveredApplication, Distribution Channel, End User, Formulation Type, Storage Condition
Key Market OpportunitiesEmerging technologies in vaccine delivery systems enhance accessibility in the Monkeypox Vaccine Treatment Market.
Key Market DynamicsRising demand for monkeypox vaccines drives innovation and competition among pharmaceutical companies in the treatment market.
Countries CoveredNorth America, Europe, APAC, South America, MEA
Leave a Comment

FAQs

What is the projected market size of the Global Monkeypox Vaccine and Treatment Market in 2024?

The Global Monkeypox Vaccine and Treatment Market is expected to be valued at 0.38 USD Billion in 2024.

What is the expected market size for the Global Monkeypox Vaccine and Treatment Market by 2035?

By 2035, the Global Monkeypox Vaccine and Treatment Market is projected to reach a value of 1.5 USD Billion.

What is the expected CAGR for the Global Monkeypox Vaccine and Treatment Market from 2025 to 2035?

The expected compound annual growth rate (CAGR) for the market from 2025 to 2035 is 13.42%.

Which region is expected to dominate the Global Monkeypox Vaccine and Treatment Market by 2035?

North America is anticipated to dominate the market, with an expected value of 0.75 USD Billion in 2035.

What will be the size of the Therapeutics segment in the Global Monkeypox Vaccine and Treatment Market in 2035?

The Therapeutics segment is expected to be valued at 0.5 USD Billion in 2035.

Which key players are leading the Global Monkeypox Vaccine and Treatment Market?

Major players in the market include Siga Technologies, Pfizer, Moderna, Sanofi, and Merck and Co.

What is the expected market value for the Diagnostics segment by 2035?

The Diagnostics segment of the market is anticipated to reach a value of 0.35 USD Billion by 2035.

How will the market size of the Asia-Pacific (APAC) region change from 2024 to 2035?

The APAC region is expected to grow from a market value of 0.05 USD Billion in 2024 to 0.2 USD Billion in 2035.

What market value is projected for the Vaccines segment in 2035?

The Vaccines segment is expected to be valued at 0.65 USD Billion in 2035.

What is the expected market value of the South America region for the Global Monkeypox Vaccine and Treatment Market in 2035?

The South America region is projected to reach a market value of 0.1 USD Billion by 2035.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓